Results 11 to 20 of about 24,588 (279)
Indian Journal of Dermatology, 2015 Omalizumab is a recombinant, humanized, monoclonal antibody against human immunoglobulin E (IgE). The US FDA has approved this molecule for chronic urticaria.
Kiran Godse +4 more
openaire +3 more sources
Asthma referrals : a key component of asthma management that needs to be addressed [PDF]
, 2017 Peer reviewedPublisher ...
Bergen, David A +3 more
core +1 more source
World Allergy Organization Journal, 2022 Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness
Nicola A. Hanania, MD +6 more
doaj +1 more source
Biologics for the treatment of chronic rhinosinusitis with nasal polyps : state of the art [PDF]
, 2019 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex upper airway disease affecting up to 11% of the population of Western Europe. In these western countries, 85% of the CRSwNP disease reveals a type 2 inflammatory pattern. In the last 15 years,
Bachert, Claus +3 more
core +1 more source
Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients
Pulmonology, 2021 Objective To estimate the cost-effectiveness of omalizumab compared with standard of care in the treatment and control of severe persistent asthma, using the outcomes from the Portuguese subpopulation of the eXpeRience registry.Methods This was a ...
A. Arrobas +4 more
doaj +3 more sources
Recovery of smell sense loss by mepolizumab in a patient allergic to dermatophagoides and affected by chronic rhinosinusitis with nasal polyps [PDF]
, 2019 Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) frequently presents with dysfunction or loss of the sense of smell, resulting in a signifcant impairment in quality of life.
Cavaliere, Carlo +7 more
core +1 more source
Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America
World Allergy Organization Journal, 2019 Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up.
Ivan Cherrez-Ojeda +15 more
doaj +1 more source
Prototype of running clinical trials in an untrustworthy environment using blockchain. [PDF]
, 2019 Monitoring and ensuring the integrity of data within the clinical trial process is currently not always feasible with the current research system.
Bhattacharya, Sanchita +2 more
core +3 more sources
Allergy & Rhinology, 2018 Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients.
Abhishek Kavati +8 more
doaj +1 more source
The future outlook on allergen immunotherapy in children: 2018 and beyond. [PDF]
, 2018 Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases.
Arasi S, Corsello G, Pajno GB, Villani A
core +2 more sources